Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JAMA editors call for increased postmarket surveillance

This article was originally published in The Gray Sheet

Executive Summary

"Independent agency for drug safety, specifically to oversee postmarket surveillance of drugs and devices," should be established, Journal of the American Medical Association editors Phil Fontanarosa, MD, Drummond Rennie, MD, and Catherine DeAngelis, MD, state in the Dec. 1 issue. A growing number of incidents involving a lack of postmarket vigilance by FDA and manufacturers, such as Merck's recent withdrawal of Vioxx, indicate an overdue need for system restructuring, the JAMA editors stress...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts